The Fra-2 transgenic mouse model of systemic sclerosis

Vascular Pharmacology

Volumn 58, Issue 3, 2013, Pages 194-201

  Maurer, Britta ^a   Distler, Jörg H W ^b   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Animal model; Fibrosis (Graphical abstract); Microangiopathy; Proliferative pulmonary vasculopathy; Systemic sclerosis

Indexed keywords

CHEMOKINE; CYTOKINE; TRANSCRIPTION FACTOR FRA 2;

ARTICLE; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MICROANGIOPATHY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SKIN CAPILLARY; SKIN FIBROSIS; SMOOTH MUSCLE FIBER; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; FOS-RELATED ANTIGEN-2; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MICE; MICE, TRANSGENIC; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84875363960     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.12.001     Document Type: Article

References (31)

1. Allanore Y., Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin. Exp. Rheumatol. 2010, 28(5 Suppl. 62):S48-S53. (Epub 2010 Nov 3) (Review).
2. Avouac J., Palumbo K., et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor beta-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 2012, 64(5):1642-1652.
3. Beyer C., Schett G., Distler O., Distler J.H. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum. 2010, 62(10):2831-2844.
4. Bouros D., Wells A.U., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002, 165(12):1581-1586.
5. Bozec A., Bakiri L., et al. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 2008, 454(7201):221-225.
6. Champion H.C. The heart in scleroderma. Rheum. Dis. Clin. N. Am. 2008, 34(1):181-190. (viii).
7. Condliffe R., Kiely D.G., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am. J. Respir. Crit. Care Med. 2009, 179(2):151-157.
8. D'Angelo W.A., Fries J.F., et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am. J. Med. 1969, 46(3):428-440.
9. Dorfmuller P., Humbert M., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum. Pathol. 2007, 38(6):893-902.
10. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 2003, 3(11):859-868.
11. Eferl R.H.P., Rath M., Popper H., Zenz R., Komnenovic V., Idarraga M.H., Kenner L., Wager E.F. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10525-10530.
12. Fernandes F., Ramires F.J., Arteaga E., Ianni B.M., Bonfá E.S., Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J. Card. Fail. 2003, 9(4):311-1317.
13. Fichtner-Feigl S., Strober W., et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 2006, 12(1):99-106.
14. Foletta V.C. Transcription factor AP-1, and the role of Fra-2. Immunol. Cell Biol. 1996, 74(2):121-133.
15. Gomez-Arroyo J., Saleem S.J., et al. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am. J. Physiol. Lung. Cell Mol. Physiol. 2012, 302(10):L977-L991.
16. Hassoun P.M., Mouthon L., et al. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 2009, 54(1 Suppl.):S10-S19.
17. Humbert M., Monti G., et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J. 1998, 11(3):554-559.
18. Mathai S.C., Hummers L.K., et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009, 60(2):569-577.
19. Matucci-Cerinic M., Denton C.P., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 2011, 70(1):32-38.
20. Maurer B., Busch N., et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009, 120(23):2367-2376.
21. Maurer B., Reich N., et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann. Rheum. Dis. 2012.
22. Overbeek M.J., Vonk M.C., et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur. Respir. J. 2009, 34(2):371-379.
23. Overbeek M.J., Mouchaers K.T., Niessen H.M., Hadi A.M., Kupreishvili K., Boonstra A., Voskuyl A.E., Belien J.A., Smit E.F., Dijkmans B.C., Vonk-Noordegraaf A., Grünberg K. Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension. Int. J. Rheumatol. 2010 2010, (pii: 604615) (Epub 2010 Sep 30). 10.1155/2010/604615.
24. Perros F., Montani D., et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008, 178(1):81-88.
25. Pietra G.G., Capron F., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J. Am. Coll. Cardiol. 2004, 43(12 Suppl. S):25S-32S.
26. Reich N., Maurer B., et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum. 2010, 62(1):280-290.
27. Sgonc R.G.M., Dietrich H., Recheis H., Gershwin M.E., Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J. Clin. Invest. 1996, 3:785-792.
28. Simonneau G., Robbins I.M., et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2009, 54(1 Suppl):S43-S54.
29. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 2007, 66(7):940-944.
30. Steen V., Denton C.P., et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl. 3):iii19-iii24.
31. Stenmark K.R., Meyrick B., et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 297(6):L1013-L1032.